ViiV's two-drug HIV regimen meets again in Phase III

ViiV Healthcare Ltd. (Brentford, U.K.) said a once-monthly two-drug regimen comprising cabotegravir and Edurant rilpivirine met the primary endpoint in the Phase III FLAIR trial as maintenance treatment in HIV-1-infected, antiretroviral therapy-naïve patients who are virologically suppressed. The company reported in August that the same regimen met the primary endpoint in the Phase III ATLAS trial as maintenance treatment in HIV-1-infected adults who are virologically suppressed on a daily antiretroviral regimen (see “J&J, ViiV’s Two-Drug Regimen Meets in Phase III for Maintenance Treatment of HIV-1 infection”).

ViiV plans to use pooled data from FLAIR and ATLAS to support regulatory submissions for the two-drug regimen...